AssetMark’s Tarsus Pharmaceuticals TARS Stock Holding History
Bought
Maintained
Sold
Other funds holding TARS
AssetMark's TARS Position: Q3 2026 in Review
AssetMark sold out of Tarsus Pharmaceuticals (TARS) in Q3 2026, closing a stake of 14 shares — an estimated $881 sold.
AssetMark first reported a position in TARS in Q2 2025 and held it in 5 quarters. The position peaked at $1.15K in Q4 2025. 176 funds tracked by Wall St. Rank hold TARS as of Q3 2026.
- AssetMark reported no remaining Tarsus Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- AssetMark sold 14 Tarsus Pharmaceuticals shares in Q3 2026, an estimated $881.
- AssetMark first reported a position in Tarsus Pharmaceuticals in Q2 2025 and held it in 5 quarters.
- AssetMark's Tarsus Pharmaceuticals position peaked at $1.15K in Q4 2025.
- 176 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.